Drugs / NXN-188
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00959751 | Jul 2009 → Feb 2010 | migraine without aura | NeurAxon Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00920686 | Jun 2009 → Mar 2010 | migraine with aura | NeurAxon Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00877838 | May 2009 → Mar 2010 | migraine with aura | Danish Headache Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXN-188 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00920686 ↗ |
| Action | Inhibit | “NXN-188 is selectively inhibits nNOS.” NCT00877838 ↗ |
| Modality | Small molecule | “new chemical entity called NXN-188” NCT00877838 ↗ |
| Route | Oral | “single oral dose of NXN-188” NCT00920686 ↗ |